Stay updated with breaking news from Assembly Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SOUTH SAN FRANCISCO, Calif., May 23, 2023 -- Assembly Biosciences, Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that... | May 23, 2023
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and... | April 18, 2023
This platform randomized clinical trial examines the effectiveness ivermectin at a targeted dose of 600 μg/kg daily compared with placebo for the treatment of e
24.10.2022 - Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement ... Seite 1
Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM, an internationally-recognized hepatologist, and authority and investigator in hepatitis clinical... | June 21, 2022